Brooks-LaSure: Medicare poised to re-evaluate coverage of new Alzheimer’s drugs
By
Alicia Lasek
Dec 12, 2022
In a Milken Institute summit session, the CMS administrator said that Medicare’s door is open to evaluating new data on emerging Alzheimer’s drug candidates.